Spanish pharma firm Uquifa, a part of the Hyderabad-headquartered Vivimed Labs, is eyeing Euro 200 million revenue over the next four years.
Uquifa, which contributes to about 60% turnover of Vivimed, had in the last fiscal clocked revenue of Euro 110 million.
The company, acquired in 2011 by Vivimed for $ 55 million, is into manufacturing of active pharmaceutical ingredients (APIs) in the global CDMO (contract development and manufacturing organisation) and generic market. It has two sites in Spain and one in Mexico that are USFDA approved and counts among clients leading drug makers globally GSK, Mylan and Gilead Lifesciences.
In an interaction here on Wednesday, Uquifa Executive Director Saurabh Gurnurkar said the company was in the process of integrating Budapest-based Soneas, a CDMO company acquired about four months ago that brought Phase I and II pre-clinical capabilities to the portfolio. During the current fiscal, with that of Soneas, Uquifa is targeting revenues of Euros 135-140 million, he said.
On the capital expenditure plans for the current fiscal, he said the company would be investing Euros 6-7 million on compliance and growth. It planned to go for a capacity expansion at the facility in Mexico. “Every year we incur 4-5 million Euros on compliance... we are spending a bit more [this year] focusing more on Mexico,” he said.
In Hyderabad, Uquifa has a research and development facility. It employed 45 of the 75 people employed by the company globally toward R&D. The annual spend of the company on R&D is 4-5% of the turnover, which would be scaled up once it gets into “more complicated chemistry.” Overall, the company has headcount of nearly 600 across four locations and produced 1,200 tonnes of API on annual basis.